Paliperidone: a new extended-release oral atypical antipsychotic

Bibliography

• NASRALLAH HA, SMELTZER DJ: Contemporary Diagnosis and Management of the Patient with Schizophrenia. Handbooks in HealthCare, Newtown, PA (2003).
   Google Scholar
• DSM IV-TR: American Psychiatric Association. 4th Edition (2000):1-992.
   Google Scholar
• LINSZEN DH, DINGEMANS PM, LENIOR ME et al.: Early detection and intervention in schizophrenia. Int. Clin. Psychopharmocol. (1998) 13(Suppl. 3):S31-S34.
   Google Scholar
• VAN BRUGGEN J, TIJSSEN J, DINGEMANS P et al.: Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int. Clin. Psychopharmocol. (2003) 18:341-346.
   PubMedGoogle Scholar
• KASPER S, LERMAN MN, MCQUADE RD et al.: Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. (2003) 6(4):325-337.
   PubMed Web of Science ®Google Scholar
• BEASLEY CM Jr, HAMILTON SH, CRAWFORD AM et al.: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine study. Eur. Neuropsychopharmacol. (1997) 7(2):125-137.
   PubMed Web of Science ®Google Scholar
• DANIEL DG, ZIMBROFF DL, POTKIN SG et al.: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6 week placebo-controlled trial. Neuropsychopharmocology (1999) 20(5):491-505.
   PubMed Web of Science ®Google Scholar
• EMSLEY RA, RANIWALLA J, BAILEY PJ et al.: A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history and demonstrated, partial response to conventional antipsychotic treatment. Int. Clin. Psychopharmocol. (2000) 15(3):121-131.
   PubMed Web of Science ®Google Scholar
• LINDSTROM E, ERIKSSON B, HELLGREN A et al.: Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin. Ther. (1997) 17(3):402-412.
   Google Scholar
• BILDER RM, GOLDMAN RS, VOLAVKA J et al.: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry (2002) 159(6):1018-1028.
   PubMed Web of Science ®Google Scholar
• LUBLIN H, EBERHARD J, LEVANDER S: Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. (2005) 20(4):183-198.
   PubMed Web of Science ®Google Scholar
• PARELLADA E, ANDREZINA R, MILANOVA V et al.: Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J. Psychopharmacol. (2005) 19(5):5-14.
   PubMed Web of Science ®Google Scholar
• NASRALLAH HA, NEWCOMER JW: Atypical antipsychotics and metabolic dysregulation: evaluating risk/benefit equation and improving the standard of care. J. Clin. Psychopharmacol. (2004) 24(5 Suppl. 1):S7-S14.
   PubMedGoogle Scholar
• NEWCOMER JW: Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J. Clin. Psychiatry (2004) 65(Suppl. 18):36-46.
   PubMedGoogle Scholar
• KANE JM, BARRETT EJ, CASEY DE et al.: Metabolic effects of treatment with atypical antipsychotics. J. Clin. Psychiatry (2004) 65(11):1447-1455.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN JA, STROUP TS, MCEVOY JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. (2005) 353 (12):1209-1223.
   PubMed Web of Science ®Google Scholar
• MCEVOY JP, MEYER JM, GOFF DC et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the CATIE schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. (2005) 80:19-32.
   PubMed Web of Science ®Google Scholar
• NASRALLAH HA: The roles of efficacy, safety and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J. Clin. Psychiatry (2007) 68(Suppl.):5-11.
   PubMedGoogle Scholar
• WEIDEN PJ, OLFSON M: Cost of relapse in schizophrenia. Schizophr. Bull. (1995) 21(3):419-429.
   PubMed Web of Science ®Google Scholar
• WU EQ, BIRNBAUM HG, SHI L et al.: The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry (2005) 66(9):1122-1129.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Practice Guidelines for the Treatment of Schizophrenia. 2nd Edition (2004):1-120.
   Google Scholar
• INVEGA® [Prescribing Information]. Titusville, NJ: Janssen (2006).
   Google Scholar
• KEITH S: Advances in psychotropic formulations. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30(6):996-1008.
   PubMed Web of Science ®Google Scholar
• CONLEY R, GUPTA SK, SATHYAN G: Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr. Med. Res. Opin. (2006) 22(10):1879-1892.
   PubMed Web of Science ®Google Scholar
• VERMEIR M, BOOM S, NAESSANS I et al.: Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Clin. Pharmacol. Ther. (2006) 79:111-118.
   Google Scholar
• GOFF DC, CATHER C, EVINS AE et al.: Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatry (2005) 66:183-194.
   PubMed Web of Science ®Google Scholar
• KANE J, CANAS F, KRAMER M et al.: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. (2007) 90:147-161.
   PubMed Web of Science ®Google Scholar
• DAVIDSON M, EMSLEY R, KRAMER M et al.: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. (2007) (In Press).
   Google Scholar
• MARDER SR, KRAMER M, FORD L et al.: Efficacy and tolerability of two fixed dosages of paliperidone extended-release tablets in the treatment of acute schizophrenia: a 6-week placebo-controlled study. Schizophr. Res. (2006) 81(Suppl. 1):56.
   Google Scholar
• KRAMER M, SIMPSON G, MACIULIS V et al.: Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharm. (2007) 27(1):6-14.
   PubMed Web of Science ®Google Scholar
• MARDER SR, DAVIS JM, CHOUINARD G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis in combined results of the North American trial. J. Clin. Psychiatry (1997) 58(12):538-546.
   PubMed Web of Science ®Google Scholar
• KAY SR, FISZBEIN A, OPLER LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. (1987) 13:261-276.
   PubMed Web of Science ®Google Scholar
• GEARHART N, BOSSIE C, CANUSO C et al.: Determination of onset of response to treatment with paliperidone extended-release in patients with acute schizophrenia [poster]. Presented at the Society of Biological Psychiatry 62nd Annual Convention & Scientific Program, San Diego, USA (17 – 19 May 2007): 844.
   Google Scholar
• MOROSINI PL, MAGLIANO L, BRAMBILLA L et al.: Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. (2000) 101(4):323-329.
   PubMed Web of Science ®Google Scholar
• MEYER J, KRAMER M, LANE R et al.: Metabolic outcomes in patients with schizophrenia treated with oral paliperidone extended-release tablets: pooled analysis of three 6-week placebo-controlled studies. Int. J. Neuropsychopharmacol. (2006) 9(Suppl. 1):282 (Abstract no. P03.204).
   Web of Science ®Google Scholar